Cabaletta Bio Appoints Biopharmaceutical Leader Scott Brun, M.D. to Board of Directors

His expertise will be particularly valuable to Cabaletta as we advance our lead program, DSG3-CAART, in mucosal pemphigus vulgaris, said Steven Nichtberger, M.D., Chief Executive Officer and Co-founder of Cabaletta.